DAIICHI SANKYO COMPANY, LIMITED Logo

DAIICHI SANKYO COMPANY, LIMITED

A global pharmaceutical firm developing novel therapies with a focus on oncology and ADCs.

4568 | T

Overview

Corporate Details

ISIN(s):
JP3475350009
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目5番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Daiichi Sankyo is a global pharmaceutical company focused on the research, development, and delivery of innovative medical solutions. The company's core business revolves around creating novel therapies, with a primary strategic focus on oncology. It is a leader in the science of antibody-drug conjugates (ADCs), a class of targeted cancer drugs. Beyond oncology, its portfolio and development pipeline include treatments for cardiovascular diseases and other specialty areas. The company manufactures and markets a range of prescription medicines, vaccines, and over-the-counter healthcare products, aiming to contribute to the enrichment of quality of life for patients worldwide by creating new standards of care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 05:22
Registration Form
確認書
Japanese 8.2 KB
2025-11-07 05:19
Interim Report
半期報告書-第21期(2025/04/01-2026/03/31)
Japanese 321.7 KB
2025-10-10 02:55
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.2 KB
2025-10-03 04:15
Registration Form
発行登録追補書類(株券、社債券等)
Japanese 130.8 KB
2025-09-05 03:06
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.3 KB
2025-08-07 05:49
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.8 KB
2025-07-17 02:04
Registration Form
発行登録書(株券、社債券等)
Japanese 24.8 KB
2025-07-09 02:32
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.2 KB
2025-06-24 06:02
Registration Form
訂正発行登録書
Japanese 8.9 KB
2025-06-24 05:36
Post-Annual General Meeting Information
臨時報告書
Japanese 25.7 KB
2025-06-23 08:40
Registration Form
訂正発行登録書
Japanese 8.9 KB
2025-06-23 07:44
Share Issue/Capital Change
臨時報告書
Japanese 31.3 KB
2025-06-20 07:20
Governance Information
内部統制報告書-第20期(2024/04/01-2025/03/31)
Japanese 23.5 KB
2025-06-20 07:20
Registration Form
確認書
Japanese 8.1 KB
2025-06-20 07:19
Annual Report
有価証券報告書-第20期(2024/04/01-2025/03/31)
Japanese 3.0 MB

Automate Your Workflow. Get a real-time feed of all DAIICHI SANKYO COMPANY, LIMITED filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DAIICHI SANKYO COMPANY, LIMITED

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DAIICHI SANKYO COMPANY, LIMITED via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.